| Week | Morning Dose | Evening Dose |
|---|---|---|
| 1 | None | 25 mg |
| 2 | 25 mg | 25 mg |
| 3 | 25 mg | 50 mg |
| 4 | 50 mg | 50 mg |
|
|
Search by color, shape and markings. click here
|
|
Check any 2 drugs for interactions. click here
|
|
|
Compare any two drugs side by side. click here
|
|
|
Medicare's drug plans are subsidized by the US federal government and offered through insurers.
|
Pending revision, the material in this section should be considered in light of more recently available information in the MEDWATCH notification at the beginning of this monograph.
Management (in combination with other anticonvulsants) of partial seizures in adults and children 2–16 years of age.
Management (in combination with other anticonvulsants) of primary generalized tonic-clonic seizures in adults and children 2–16 years of age.
Management (in combination with other anticonvulsants) of seizures associated with Lennox-Gastaut syndrome in adults and children ≥2 years of age.
Prophylaxis of migraine headache in adults.
Efficacy in the acute management (i.e., abortive therapy) of migraine headache not established.
Pending revision, the material in this section should be considered in light of more recently available information in the MEDWATCH notification at the beginning of this monograph.
Administer orally without regard to meals.
Capsule/sprinkle formulation is bioequivalent to immediate-release tablet and may be substituted as a therapeutic equivalent.
Swallow capsules whole.
Alternatively, open capsule and sprinkle entire contents on soft food (e.g., applesauce, custard, ice cream, oatmeal, yogurt, pudding); swallow immediately without chewing.
Drinking fluids immediately may help to ensure that all of the mixture is swallowed.
Do not store the sprinkle/food mixture for use at a later time.
Tablets preferably should be swallowed intact and not broken or chewed because of the bitter taste.
If patient has difficulty in swallowing tablets, the tablets may be crushed and mixed with oatmeal or applesauce; use immediately since stability cannot be ensured.
If tablets are broken, use immediately since stability beyond a brief period cannot be ensured. Discard any unused portion.
Pending revision, the material in this section should be considered in light of more recently available information in the MEDWATCH notification at the beginning of this monograph.
Initially, 25 mg (or less based on a range of 1–3 mg/kg daily) given nightly for the first week in children 2–16 years of age. Increase dosage at 1- or 2-week intervals in increments of 1–3 mg/kg daily, administered in 2 divided doses, to achieve optimal clinical response.
Maintenance, 5–9 mg/kg daily in 2 divided doses.
Alternatively, some clinicians recommend an initial dosage of 0.5–1 mg/kg daily, with slow titration (in increments of 1–3 mg/kg every other week or in increments of 0.5–1 mg/kg per week) to obtain optimal efficacy with minimal adverse effects.
Initially, 25–50 mg daily. Increase dosage at weekly intervals in increments of 25–50 mg to achieve optimal clinical response.
Recommended maintenance dosage is 200–400 mg daily, administered in 2 equally divided doses (morning and evening).
Titration in increments of 25 mg/week is associated with a lower incidence of cognitive and psychiatric adverse effects and lower discontinuance rates but may delay the time to reach an effective dosage.
Dosages >400 mg daily generally have not produced substantial additional improvement, but may improve seizure control in some patients, if tolerated.
Initially, 25–50 mg daily. Increase dosage at weekly intervals in increments of 25–50 mg to achieve optimal clinical response.
Recommended maintenance dosage is 400 mg daily, administered in 2 equally divided doses (morning and evening).
Titration in increments of 25 mg/week is associated with a lower incidence of cognitive and psychiatric adverse effects and lower discontinuance rates but may delay the time to reach an effective dosage.
Manufacturer makes no specific dosage recommendations; in 1 controlled trial, topiramate was initiated at dosage of 1 mg/kg and titrated over 2 weeks to target dosage of approximately 6 mg/kg daily.
Recommended total daily dosage is 100 mg, administered in 2 divided doses. Titrate therapy using the following schedule in Table 1.
| Week | Morning Dose | Evening Dose |
|---|---|---|
| 1 | None | 25 mg |
| 2 | 25 mg | 25 mg |
| 3 | 25 mg | 50 mg |
| 4 | 50 mg | 50 mg |
Titrate dosage based on clinical outcome. Use longer intervals between dose adjustments if required.
Dosages >1.6 g daily in patients with seizure disorders have not been studied.
Clearance may be decreased; however, manufacturer makes no specific recommendations regarding dosage adjustment.
If Clcr is <70 mL/minute per 1.73 m2, decrease daily adult dosage by 50%. Patients with renal impairment will require a longer time to reach steady state at each dosage level.
Patients undergoing hemodialysis may require a supplemental dose following dialysis session; base amount on duration of dialysis, clearance rate of dialysis system, and the patient’s effective renal clearance of topiramate.
If Clcr <70 mL/minute per 1.73 m2, dosage adjustment may be necessary. (See Renal Impairment under Dosage and Administration.)
Last Updated: June 01, 2009